Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?

Francesco Maura, Ross Firestone, Saad Z Usmani

Open source

DOI: 10.1016/s0140-6736(26)01199-2
Published: 2026-07
Container: The Lancet
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-01199-2,
  title = {Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?},
  author = {Francesco Maura and Ross Firestone and Saad Z Usmani},
  year = {2026},
  journal = {The Lancet},
  doi = {10.1016/s0140-6736(26)01199-2},
  url = {https://doi.org/10.1016/s0140-6736(26)01199-2}
}

RIS

TY  - JOUR
TI  - Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?
AU  - Francesco Maura
AU  - Ross Firestone
AU  - Saad Z Usmani
PY  - 2026
JO  - The Lancet
DO  - 10.1016/s0140-6736(26)01199-2
UR  - https://doi.org/10.1016/s0140-6736(26)01199-2
ER  -

APA

Maura, F., Firestone, R., & Usmani, S. Z. (2026). Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?. The Lancet. https://doi.org/10.1016/s0140-6736(26)01199-2

Source records

crossref · retrieved 2026-09-27T00:36:28.750Z